How is the GPhC policing online weight-loss supply in 2026?

What changed in GPhC enforcement in 2026?

The regulator stopped explaining its weight-loss rules and started testing them. The rules themselves are not new. The GPhC's guidance for pharmacies providing services at a distance has required independent verification of weight, height or BMI since February 2025. The six checks it demands are set out in our guide to the verification duties. This article is about what happens when a pharmacy does not do them.

The first move came on 13 January 2026, when the GPhC published an updated inspection framework to replace the 2019 version. For weight-loss services it is blunt: a pharmacy that does not independently verify a patient's weight, height or BMI will fail its inspection. Websites offering prescribing services must name the prescriber, give the address of the prescribing service and say whether the prescriber is a doctor or a non-medical prescriber.

The second move was public. On 5 January 2026 the GPhC responded to an ITV News report about inappropriate online supply of weight-management medicines. Its Chief Pharmacy Officer, Roz Gittins, said all three pharmacies named had been inspected. Two were not meeting all of the standards and one remained under investigation.

The third move was to the intake. On 18 February 2026 the GPhC published acceptance criteria for concerns, after receiving more than 7,500 in the previous year, its highest ever. Then, on 26 February 2026, it reported the effect on weight-loss cases. Concerns about the prescribing and supply of weight-management medicines peaked at 429 in the second quarter of 2025/26 and fell to 236 in the third. The regulator credited the end of an acute pricing and supply problem and "better compliance with our guidance, particularly among online pharmacies". It added that it "will continue to take action when standards are not met".

What did the April 2026 themed review find?

It found that most pharmacies meet the standards and that the failures cluster in three places. The GPhC published the review on 24 April 2026. It analyses inspection reports and concerns from January 2024 to December 2025.

On the inspection side, 77 inspection reports referenced weight-management services, about 5 per cent of all inspections in the period. Those reports assessed 2,002 individual standards. Of them, 106, or 5.3 per cent, were recorded as not met or requiring improvement. Bricks-and-mortar pharmacies accounted for 62 of the 106 and online pharmacies for 44.

On the concerns side, the GPhC reviewed 1,307 concerns referencing weight-management medicines or services. They rose from 208 in 2024 to 1,099 in 2025. Members of the public raised 76 per cent. Online pharmacies attracted 49 per cent of concerns and bricks-and-mortar pharmacies 26 per cent; the rest did not specify a setting. The review sorts them into six themes.

One detail deserves attention. Inadequate BMI verification was the third most frequently reported area of concern at 11 per cent, with 72 per cent of those reports coming from the public. Patients now know what a compliant check looks like, and they report the pharmacies that skip it.

Which failures get a pharmacy marked down?

Governance failures, not clinical exotica. The review's narrative for standard 1.1 is specific. Risk assessments were "absent, only partially completed, insufficiently documented, or not reviewed and updated in a timely manner". Pharmacies could not show that the third-party prescribing services they worked with had their own risk assessments or clinical safeguards. They could not demonstrate processes for independently verifying a person's weight and BMI. And they lacked follow-up arrangements to make sure ongoing treatment stayed appropriate and safe.

Standard 1.6 failures were about the record of the decision. Pharmacies "did not provide appropriate documentation of clinical consultations and prescribing decisions". Records lacked the detail needed to show that a safe and clinically appropriate decision had been made. That is the finding that catches otherwise decent services. If the record does not show who verified what, when, and against which evidence, the inspector marks the standard down.

The concerns data adds the practices the regulator now recognises on sight. Reports described supply to people with a history of eating disorders without BMI verification or a thorough assessment. Some pharmacies asked for photographs in tight-fitting clothes or underwear as evidence of weight, and wrongly told patients the GPhC required it. One online questionnaire listed the contraindicated medicines, which made it easier to give inaccurate answers and avoid being declined. Other reports described medication titrated automatically without clinical review, even after the patient had reported adverse effects.

What enforcement action can the GPhC take against a pharmacy?

A ladder with six rungs, set out in the GPhC's registered pharmacies enforcement policy. The first rung is not statutory. A pharmacy that fails a standard must send an improvement action plan within five working days of the inspection. Inspectors set completion timescales of 10, 20 or 60 working days depending on the issue. The plan is published with the report, and a re-inspection follows up to six months after the final report is sent.

The statutory rungs follow when a plan is not completed or when there is a serious risk to patient safety. The GPhC can impose conditions on the premises registration, with notice or immediately. It can serve an improvement notice, which gives at least 28 days to comply. Failure to comply with an improvement notice triggers referral to the Fitness to Practise Committee for disqualification proceedings. That committee can suspend premises pending a hearing, remove premises from the register and disqualify the owner. The powers sit in the Pharmacy Order 2010 and in sections 74D, 74E, 80, 82 and 82A of the Medicines Act 1968.

How often are the statutory rungs used? The GPhC's 2024/25 annual report says it took enforcement action against "at least 12 pharmacies in relation to their supply of weight-management medicines". It acted against "at least nine other pharmacies" for unverified online supply. The Pharmaceutical Journal's analysis of regulator data, published on 9 April 2025, gives the longer run. The figures below are from those two sources.

Conditions, not improvement notices, are the regulator's preferred tool for online pharmacies. Sixty-six conditions notices against 14 improvement notices tells you that. A conditions notice restricts what the pharmacy may do, and the April 2026 review lists breaching enforcement action among the misconduct concerns it received. Our earlier analysis of what the GPhC's enforcement actions mean for online pharmacies covers the pre-2026 cases in more detail.

What are fitness-to-practise panels doing to individuals?

Suspending and, in the worst cases, removing pharmacists for online supply that relied on questionnaires. Enforcement against premises and fitness to practise against people run on separate tracks, and 2026 has produced determinations on both.

The clearest weight-loss case is the one reported by Pharmacy Magazine on 10 February 2026. A superintendent pharmacist in Hove had prescribed Saxenda to two patients between 2019 and 2021, mainly on the basis of an online questionnaire. She did not access GP records or hold face-to-face consultations, and she oversaw a questionnaire-based model with no risk assessments. The committee found her prescribing was not in accordance with NICE guidance and suspended her for three months in October 2025. At the review hearing she was allowed to return, having acknowledged that "commercial convenience had been allowed to override patient safety".

The higher-volume cases involve high-risk medicines rather than weight-loss medicines specifically, but the reasoning transfers. On 7 April 2026 a former UK Meds pharmacist was suspended for 12 months. He had approved 70,618 prescriptions between October 2019 and August 2022, thousands of them for high-risk medicines, relying on web questionnaires and not reviewing order history. The committee called the failures "repeated and widespread". On 22 May 2026 Chemist and Druggist reported a superintendent struck off and two pharmacists suspended for 12 months each. All three had supplied high-risk medicines online without "adequate information" about their patients.

Three lessons run through the determinations. Volume and speed are treated as evidence of a transactional model, not as mitigation. Working through a third-party platform does not dilute the individual registrant's responsibility for each supply. And a superintendent who designs or tolerates the model answers for it personally, as our guide to the superintendent's online responsibilities explains.

How are online pharmacies performing at inspection?

Better than in 2025, but still worse than bricks-and-mortar pharmacies, and not all of them have been inspected. The Pharmaceutical Journal analysed new online registrations on 5 February 2026. Of 68 online pharmacies registered between January and July 2025, 38, or 56 per cent, were inspected within the GPhC's six-month target. The remaining 44 per cent were not, which the GPhC attributed mainly to pharmacies not yet being fully operational. The same analysis found 81 per cent of online pharmacies met all standards in the latest quarter.

The longer baseline comes from the PJ's April 2025 analysis. Between 1 April 2022 and 14 January 2025, 24 of 230 distance-selling pharmacies inspected, 10 per cent, failed to meet all standards. For bricks-and-mortar pharmacies the figure was 5 per cent. Of the 24 failing online pharmacies, 22 failed on governance.

Capacity is rising on both sides. Speaking at the Clinical Pharmacy Congress on 8 May 2026, GPhC chief executive Kathie Cashell said inspection activity was up 60 per cent. The regulator delivered more than 2,000 inspections in 2025/26. She also said about 9,500 concerns a year now come through the door, of which about 6 per cent lead to a full investigation.

What is still coming?

A written policy on the top of the enforcement ladder, and a government response on private prescribing. The GPhC told its Council in December 2025 that it had "yet to develop an overarching policy on the use of our disqualification powers". It aims to publish one in summer 2026. Pharmacy Magazine reported on 8 December 2025 that it may cover interim suspension of premises as well as disqualification. Until then, the GPhC has said it will not pursue full disqualification hearings where an owner has already removed every premises from the register.

The Department of Health and Social Care ran a UK-wide call for evidence on private prescribing that closed on 4 November 2025. It covered private prescriptions by UK prescribers, prescriptions from EEA and Swiss prescribers dispensed in the UK, and private patient group directions. The government's response is awaited. Any change will land on weight-loss services first, because that is where the volume is.

Advertising enforcement is already joint. The Committee of Advertising Practice, the MHRA and the GPhC issued an enforcement notice on prescription-only weight-management medicines in April 2025. By July 2025 the ASA had reviewed advertising from 35 pharmacies and issued rulings against six GPhC registrants. What you can and cannot say is covered in our guide to advertising weight-loss medicines.

What should an online operator do now?

Build the evidence the review says inspectors could not find. The recommended actions in the April 2026 review read as an inspection agenda, and every one of them is a record you either hold or do not.

The follow-up item is the one most services under-build. What monitoring a defensible service runs, and how to evidence it, is the subject of our guide to weight-loss monitoring requirements. For the framework inspectors now mark against, see what GPhC inspectors look for in 2026.

Key takeaways

FAQs